Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Monica Smith

Nurse Practitioner, Family Wheeling, WV Nurse Practitioner

NPI 1639280399 CMS profile 10670507

2121 Eoff St, Wheeling, WV 26003

Open in the dashboard

General payments

$6,704

393 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monica Smith of Wheeling, WV is reported in the CMS Open Payments database as having received $6,704 across 393 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,235 70
2024 General $1,212 61
2023 General $902 61
2022 General $1,231 75
2021 General $2,125 126

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monica Smith
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Monica Smith were reported at $1,235. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Monica Smith Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,125 $124 $35–$379 $132
2022 $1,231 $141 $44–$430 $149
2023 $902 $154 $49–$476 $160
2024 $1,212 $165 $51–$504 $164
2025 $1,235 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,914 136 payments
  2. Alkermes, Inc. $892 48 payments
  3. Teva Pharmaceuticals USA, Inc. $762 41 payments
  4. Neurocrine Biosciences, Inc. $758 43 payments
  5. ITI, Inc. $522 31 payments
  6. Vanda Pharmaceuticals Inc. $353 18 payments
  7. Otsuka America Pharmaceutical, Inc. $315 20 payments
  8. Janssen Pharmaceuticals, Inc $283 16 payments
  9. E.R. Squibb & Sons, L.L.C. $256 13 payments
  10. Indivior Inc. $166 8 payments
  11. Other $482 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,657 392 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,726 121 payments
  2. INGREZZA $636 36 payments
  3. ARISTADA Cns $610 32 payments
  4. ARISTADA Cns $610 32 payments
  5. ARISTADA INITIO $571 30 payments
  6. LYBALVI Cns $419 22 payments
  7. LYBALVI Cns $380 20 payments
  8. FANAPT $353 18 payments
  9. CAPLYTA $341 21 payments
  10. AUSTEDO $330 20 payments
  11. Other $3,513 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,720

Median for Nurse Practitioner: 389

Drug cost

$184,975

Median for Nurse Practitioner: $21,885

Branded share of claims

28.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 47 $71,018
Fanapt Iloperidone Brand 14 $25,492
Caplyta Lumateperone Tosylate Brand 12 $20,498
Vivitrol Naltrexone Microspheres Brand 11 $16,969
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 93 $8,733
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 29 $7,628
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 18 $6,128
Paliperidone Er Paliperidone Brand 20 $4,579
Atomoxetine Hcl Generic 25 $2,521
Oxcarbazepine Generic 66 $2,444

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$22,285

Medicare's payments for the services billed

Medicare patients

61

Average age 55

Services billed

370

26 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 61%
High blood pressure 52%
Arthritis 28%
Diabetes 25%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
$236 — —
VRAYLAR
$150 47 —
Austedo XR
$132 — —
UZEDY
$90 — —
Kerendia
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

393 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record